Quantitation of ursolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study

Xia, Yuanyuan; Wei, Guangli; Si, Duanyun; Liu, Changxiao

doi:10.1016/j.jchromb.2010.11.037

Cited by 59 publications

(54 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 However, based on the unpublished preclinical studies on nanoliposomal UA in In the present study, we determined the total UA concentration in human plasma by UPLC-MS/MS. 26 The LLOQ under the present conditions was 10 ng/mL. The results indicated that the method was specific, sensitive, and convenient for the determination of the UA concentration in biological samples.…”

Section: Discussionmentioning

confidence: 59%

See 1 more Smart Citation

A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors

Zhu¹,

Zhou²,

Zhao³

et al. 2013

IJN

View full text Add to dashboard Cite

Background: Ursolic acid is a promising anticancer agent. The current study aims to evaluate the single-and multiple-dose pharmacokinetics (PK) as well as the safety of ursolic acid nanoliposomes (UANL) in healthy volunteers and in patients with advanced solid tumors. Methods: Twenty-four healthy volunteers in the single-dose PK study were divided into three different groups, which received 37, 74, and 98 mg/m 2 of UANL. Eight patients in the multiple-dose PK study were administered with 74 mg/m 2 of UANL daily for 14 days. The UA plasma concentrations were determined using ultra-performance liquid chromatograph-tandem mass spectrometry. Results:The plasma concentration profiles of all subjects were characterized by a biexponential decline after infusion. The mean peak plasma concentration (C max ) increased linearly as a function of the dose (r = 0.999). The mean area under the plasma concentration-time curve (AUC) from 0 to 16 hours also increased proportionally with dose escalation (r = 0.998). However, the clearance was constant over the specific dose interval. In the multiple-dose PK study, the trough and average concentrations remained low. The mean AUC, half-life, C max , time to C max , and the volume of distribution on the first day were similar to those on the last day. All subjects tolerated the treatments well. Most UANL-associated adverse events varied from mild to moderate. Conclusions: UANL exhibits relatively linear PK behavior with dose levels from 37 mg/m 2 to 98 mg/m 2 . No drug accumulation was observed with repeated doses of UANL. The intravenous infusion of UANL was well tolerated by healthy volunteers and patients with advanced tumors.

show abstract

Section: Discussionmentioning

confidence: 59%

“…26 The lower limit of quantitation (LLOQ) for UANL was 10 ng/mL, and the assays were linear from 10 ng/mL to 5000 ng/mL. The mean extraction recovery of UANL was 73.2%, and the matrix ion suppression ranged from −11.4% to −5.6%.…”

Section: Analytical Assaysmentioning

confidence: 95%

A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors

Zhu¹,

Zhou²,

Zhao³

et al. 2013

IJN

View full text Add to dashboard Cite

show abstract

“…Piperine In case of ursolic acid the parent ion isolated in Q1 (455.1) passed through Q2 (9 eV) without fragmentation, while in Q3 (455), the same ion was monitored (Xia et al, 2011). This could not be collided into fragments when collision energy was lower than 40 eV, or no dominant product ion were detected if collision energy was higher than 40 eV, which indicated that routine MRM with different parent and product ion was not suitable for ursolic acid quantitation.…”

Section: Optimization Of Ms/ms Conditionsmentioning

confidence: 99%

Quantitative determination of chemical constituents of Piper spp. using UPLC–ESI–MS/MS

Chandra

Pandey

Srivastva

et al. 2015

Industrial Crops and Products

View full text Add to dashboard Cite

“…Recently an ultra-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) method with high selectivity, sensitivity and throughput was established and validated for quantitation of total ursolic acid in human plasma. This assay exhibited good linearity over the range of 10-5000 ng/mL for ursolic acid in human plasma with a lower limit of quantitation of 10 ng/mL [87]. In another study, Chen et al [88] developed a method using liquid chromatography and mass spectrometry to determine the concentration of ursolic acid in rat plasma.…”

Section: Pharmacokinetics Of Ursolic Acidmentioning

confidence: 99%

Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies

Shanmugam

Dai

Kumar

et al. 2013

Biochemical Pharmacology

292

205

View full text Add to dashboard Cite

Quantitation of ursolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study

Cited by 59 publications

References 8 publications

A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors

A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors

Quantitative determination of chemical constituents of Piper spp. using UPLC–ESI–MS/MS

Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies

Contact Info

Product

Resources

About